title: [High-dose intravenous immunoglobulin treatment].
abstract: High-dose intravenous immunoglobulin (VIG) treatment for the acute stage of Kawasaki disease (KD) has shown to be effective and safe. But it is known that 15% to 20% of patients are resistant to initial MG. Initial VIG treatment (2 g/kg) and aspirin (30-50 mg/kg/day) within 9th day of illness has a potentially risk of coronary arterial lesions. It should be mentioned that prediction of resistant cases in IVIG with KD can be detected by information from patients before and early after start of treatment. Some scoring systems are available for the prediction.
authors.affiliation: Chilren's Medical Center, Showa University Northern Yokohama Hospital.
authors.forename: Zenji
authors.initials: Z
authors.lastname: Nonaka
mesh_terms: D002675:Child, Preschool; D005440:Fluid Therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D007223:Infant; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*
chemical_list: D016756:Immunoglobulins, Intravenous